31 Review on cardiac toxicity [18] Van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84. [19] Mariette C, Seitz JF, Maillard E, Mornex F, Thomas PA, Raoul J, Boige V, Pezet D, Genet C BL and FF de CD. Surgery alone versus chemoradiotherapy followed by surgery for localised esophageal cancer : analysis od a randomised controlled phase III trial FFCD 9901. J Clin Oncol 2010;28:abstract 4005. [20]Bosch DJ, Muijs CT, Mul VEM, Beukema JC, Hospers G a P, Burgerhof JGM, et al. Impact of Neoadjuvant Chemoradiotherapy on Postoperative Course after Curative-intent Transthoracic Esophagectomy in Esophageal Cancer Patients. Ann Surg Oncol 2013;21. [21] “Port Meta-analysis Trialists group.”Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257–63. [22] Stewart F a. Mechanisms and dose-response relationships for radiation-induced cardiovascular disease. Ann ICRP 2011;41:72–9. [23]Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241–52. [24]Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013;39:974–84. [25]Nuver J, Smit a J, Sleijfer DT, van Gessel a I, van Roon a M, van der Meer J, et al. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 2005;35:99– 103. [26]Altena R, de Haas EC, Nuver J, Brouwer C a J, van den Berg MP, Smit a J, et al. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 2009;100:1861–6. [27]Komamura K. Similarities and Differences between the Pathogenesis and Pathophysiology of Diastolic and Systolic Heart Failure. Cardiol Res Pract 2013;2013:824135. [28]Barjaktarovic Z, Shyla A, Azimzadeh O, Schulz S, Haagen J, Dörr W, et al. Ionising radiation induces persistent alterations in the cardiac mitochondrial function of C57BL/6 mice 40 weeks after local heart exposure. Radiother Oncol 2013;106:404–10. [29]Gabriels K, Hoving S, Seemann I, Visser NL, Gijbels MJ, Pol JF, et al. Local heart irradiation of ApoE(-/-) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis. Radiother Oncol 2012;105:358–64. [30]Seemann I, Gabriels K, Visser NL, Hoving S, te Poele J a, Pol JF, et al. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother Oncol 2012;103:143–50. [31] Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21:3431–9. [32]McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson N-O, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011;100:167–75. [33]Lorenzen EL, Taylor CW, Maraldo M, Nielsen MH, Offersen B V, Andersen MR, et al. Interobserver variation in delineation of the heart and left anterior descending coronary artery in radiotherapy for breast cancer: a multi-centre study from Denmark and the UK. Radiother Oncol 2013;108:254–8. [34]Langendijk J a, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013;107:267–73. 2
RkJQdWJsaXNoZXIy MTk4NDMw